Since DDX10 is a strong enhancer of α-synuclein-induced toxicity (150), we can employ SDL interaction between DDX10 and α-synuclein and use α-synuclein inhibitors as promising therapeutics for cancer, such as melanoma. This evidence concerns the gene DDX10 and cancer.